Published in J Biol Chem on February 25, 1982
Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids. Br J Clin Pharmacol (1988) 1.03
Angiotensin II-induced hypertension in the rat. Effects on the plasma concentration, renal excretion, and tissue release of prostaglandins. J Clin Invest (1983) 0.88
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
[The heart ventricle wall in digital subtraction angiocardiography]. Rofo (1989) 1.97
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost (2008) 1.80
Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor. Kidney Int (2000) 1.71
Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr (2002) 1.64
Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost (2003) 1.54
Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost (2000) 1.48
Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza. J Thromb Haemost (2010) 1.47
Normal values of blood pressure self-measurement in view of the 1999 World Health Organization-International Society of Hypertension guidelines. Am J Hypertens (2000) 1.46
The lymphocyte Na+/H+ antiport: activation in primary hypertension and during chronic NaCl-loading. Eur J Clin Invest (1994) 1.41
[Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study]. Dtsch Med Wochenschr (2004) 1.40
Antihypertensive drug treatment and fibrinolytic function. Am J Hypertens (1998) 1.39
Acute saline infusion induces extracellular acidification and activation of the Na+/H+ exchanger in man. Eur J Clin Invest (1997) 1.39
Combined von Willebrand factor deficiency and factor XII deficiency. Thromb Haemost (2000) 1.38
Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. J Thromb Haemost (2009) 1.33
Purified verotoxins of Escherichia coli O157:H7 decrease prostacyclin synthesis by endothelial cells. Microb Pathog (1988) 1.22
Luminography--a new, highly sensitive visualization method for electrophoresis. Electrophoresis (1991) 1.14
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost (2006) 1.14
Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost (2009) 1.13
Functional and metabolic studies on red blood cell sodium transport in chronic uremia. Nephron (1976) 1.10
Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol (1980) 1.10
Albuminuria and peripheral arterial disease: results from the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis (2008) 1.10
Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension (1995) 1.09
Interaction of conventional and antikaliuretic diuretics with the renal prostaglandin system. Clin Sci (Lond) (1980) 1.08
Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost (2004) 1.08
Dietary administration of eicosapentaenoic and linolenic acid increases arterial blood pressure and suppresses vascular prostacyclin synthesis in the rat. Prostaglandins (1982) 1.07
The renal endothelin system in the Prague hypertensive rat, a new model of spontaneous hypertension. Clin Sci (Lond) (1999) 1.06
Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood (1984) 1.05
Circulating inhibitor of sodium-potassium-activated adenosine triphosphatase after expansion of extracellular fluid volume in rats. Clin Sci Mol Med (1977) 1.04
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet (1981) 1.02
Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors. J Clin Invest (1987) 1.01
von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost (2011) 1.01
First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost (1999) 1.00
Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells. Atherosclerosis (1997) 0.99
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol (2001) 0.96
Decreased plasma concentration of von Willebrand factor antigen (VWF:Ag) in patients with glycogen storage disease type Ia. J Inherit Metab Dis (2005) 0.95
Genetic defects in von Willebrand disease type 3 in Indian and Greek patients. Blood Cells Mol Dis (2008) 0.95
Luminography--an alternative assay for detection of von Willebrand factor multimers. Thromb Haemost (1988) 0.95
Elevated serum concentrations of soluble adhesion molecules in coronary artery disease and acute myocardial infarction. Eur J Med Res (1997) 0.95
Urinary -glucuronidase activity in renal disease. Arch Intern Med (1973) 0.94
Experimental Fanconi syndrome. I. Effect of maleic acid on renal cortical Na-K-ATPase activity and ATP levels. J Lab Clin Med (1970) 0.94
Prevalence of factor V Leiden in children with thrombo-embolism. Eur J Pediatr (1996) 0.94
Natriuretic hormone - a circulating inhibitor of sodium- and potassium-activated adenosine triphosphatase. Its potential role in body fluid and blood pressure regulation. Klin Wochenschr (1981) 0.93
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost (2007) 0.93
Von Willebrand Disease type 2M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost (2000) 0.93
A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. J Thromb Haemost (2007) 0.92
Inhibition of intestinal (Na+--K+)-ATPase in experimental uremia. Clin Chim Acta (1974) 0.92
Acquired von Willebrand syndrome in children with patent ductus arteriosus. Heart (2002) 0.92
Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood (2001) 0.91
Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet (1995) 0.91
Acquired von Willebrand disease in an infant. Resolution by interventional occlusion of patent ductus arteriosus. Thromb Res (2001) 0.90
The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol (1996) 0.90
Converting enzyme inhibition and vascular prostacyclin synthesis: effect of kinin receptor antagonism. Eur J Pharmacol (1990) 0.90
Angiotensin II-induced stimulation of p21-activated kinase and c-Jun NH2-terminal kinase is mediated by Rac1 and Nck. J Biol Chem (2001) 0.89
Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood (1986) 0.89
von Willebrand's disease: a report from a meeting in the Åland islands. Haemophilia (2012) 0.89
Large deletions identified in patients with von Willebrand disease using multiple ligation-dependent probe amplification. J Thromb Haemost (2011) 0.89
Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet (1994) 0.88
High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP). Clinical effects. Blut (1984) 0.88
Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol (2000) 0.88
Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney Blood Press Res (2000) 0.87
Interaction of bemetizide and indomethacin in the kidney. Br J Clin Pharmacol (1983) 0.87
Membrane sodium-proton exchange and primary hypertension. Hypertension (1993) 0.87
A novel stop mutation truncating critical regions of the cardiac transcription factor NKX2-5 in a large family with autosomal-dominant inherited congenital heart disease. Clin Res Cardiol (2007) 0.87
Effect of extracellular volume expansion on renal Na-K-ATPase and cell metabolism. Nephron (1974) 0.87
Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci U S A (1996) 0.87
Deep intronic 'mutations' cause hemophilia A: application of next generation sequencing in patients without detectable mutation in F8 cDNA. J Thromb Haemost (2013) 0.86
Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype. J Thromb Haemost (2010) 0.86
Arterial blood pressure. Correlation with erythrocyte count, hematocrit, and hemoglobin concentration. Am J Hypertens (1991) 0.85
Prostaglandin-independent protection by furosemide from oliguric ischemic renal failure in conscious rats. Kidney Int (1980) 0.85
Rat renal, aortic and pulmonary endothelin-I receptors: effects of changes in sodium and water intake. Clin Sci (Lond) (1993) 0.85
Renal venous renin activity in various forms of curable renal hypertension. Clin Nephrol (1981) 0.85
Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis. Thromb Haemost (2009) 0.85
Sodium-proton exchange and primary hypertension. An update. Hypertension (1995) 0.85
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia (2008) 0.85
[Classification of von Willebrand disease]. Hamostaseologie (2004) 0.84
The role of prostaglandins in the natriuresis of acutely salt-loaded rats. Nephron (1977) 0.84
In vitro inhibition of Na-K-ATPase by trace metals: relation to renal and cardiovascular damage. Nephron (1986) 0.84
Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens (1997) 0.84
Platelet Na(+)-H+ exchanger activity in normotensive and hypertensive subjects: effect of enalapril therapy upon antiport activity. J Hypertens (1992) 0.84
Role of prostaglandins in the regulation of renal water excretion. Kidney Int (1981) 0.84
Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry. Am J Clin Pathol (2001) 0.83
Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies. Eur Neuropsychopharmacol (1992) 0.83
Interaction of renal prostaglandins with the renin-angiotensin and renal adrenergic nervous systems in healthy subjects during dietary changes in sodium intake. Clin Sci (Lond) (1985) 0.83
Excitation energy transfer in Rhodopseudomonas sphaeroides chromatophore membranes fused with liposomes. FEBS Lett (1985) 0.83